Please login to the form below

Not currently logged in
Email:
Password:

J&J's enzyme treatment approved

The US Food and Drug Administration has announced the approval of Pancreaze, Johnson & Johnson's pancreatic enzyme product

The US Food and Drug Administration (FDA) has announced the approval of Pancreaze (pancrelipase), Johnson & Johnson's (J&J) pancreatic enzyme product (PEP) available as a delayed release capsule.

This is the third approval for a PEP by the FDA since 2009, following Abbott's Creon (pancreatin), and Eurand Pharmaceuticals' Zenpep (pancrelipase), and increases quality assured supply of the treatment for the estimated 200,000 US patients in need of the product.

Unapproved versions of the treatment have been available for several years, though the FDA called for makers of unapproved PEPs to cease the manufacture and distribution of unapproved products by April 28, 2010.

The agency has said it is working with various healthcare organisations and drug manufacturers to raise awareness of the availability of PEPs, advising patients with questions about the product to talk to their healthcare provider.

PEPs are nutritional supplements that improve the food digestion process in patients who do not have enough pancreatic enzymes. These patients include people with conditions such as pancreatic tumours, cystic fibrosis, and those who have had all or part of their pancreas removed.

"The approval of Pancreaze, along with Creon and Zenpep, allows patients and healthcare professionals to choose the approved pancreatic enzyme product that is appropriate for them," said Dr Donna Griebel, director of the FDA's Division of Gastroenterology Products.

13th April 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics